Colistimethate (Coly-Mycin M)

A cystic fibrosis patient may have died as a result of using the antibiotic Colistimethate that had been premixed by a pharmacy into a liquid for inhalation with a nebulizer. The FDA has not approved this use for Colistimethate (marketed as Coly-Mycin M and generics). However, in treating CF patients with Pseudomonas infections, colistimethate is often mixed with sterile water to form a solution just prior to inhalation via nebulizer. After mixing with sterile water and a buffer, colistimethate undergoes spontaneous hydrolysis to the bioactive form colistin. A component of colistin, polymyxin E1, is toxic to lung tissue. Premixing colistimethate into an aqueous solution and storing it for longer than 24 hours results in increased concentrations of colistin in solution, increasing the potential for lung toxicity. Both product liability and malpractice issues may be involved in a Colistimethate lawsuit.

Lawyer Fred Pritzker, has over 30 years of malpractice and product liability lawsuit experience and has recovered millions for clients. He is nationally recognized and has been interviewed by the New York Times, Wall Street Journal, and other publications. In recognition of his accomplishments, he has been selected by other lawyers for inclusion in The Best Lawyers in America.

FDA Colistimethate (Coly-Mycin M) Public Health Advisory
The FDA has received a report about the death of a patient with cystic fibrosis (CF) who used the antibiotic Colistimethate that had been premixed by a pharmacy into a liquid for inhalation with a nebulizer. Colistmethate is marketed as Coly-Mycin M and generics. A nebulizer is a device that turns liquid medicine into a mist which is breathed in by patients to deliver the medication directly to their lungs. Nebulizers are commonly used by patients with CF. The Colistimethate that was used by this patient had been prepared and dispensed by the pharmacy as a ready-to-use liquid.

Colistimethate is FDA approved only for injection into a vein or a muscle; it is not FDA approved for use as a liquid to be inhaled via nebulizer. When Colistimethate is mixed into a liquid form, the product begins to break down into other chemicals that can damage lung tissue. Colistimethate is used to treat infections caused by certain types of bacteria, including the bacteria Pseudomonas aeruginosa, a germ that is known to cause serious lung infections in patients with CF.

In light of this reported patient death, FDA offers the following recommendations:

If using the liquid form in a nebulizer, it should be used promptly after being mixed.
Patients should discard any unused pre-mixed liquid form of Colistimethate. [This is the FDA recommendation. Pritzker | Olsen, P.A. recommends not using it and keeping it in a safe place until it is certain that the patient's lungs were not adversly affected by the Colistimethate. If it is discarded, valuable evidence may be lost.]
Healthcare professionals who use Colistimethate to treat patients with CF should be aware of the potential for serious and life threatening side effects from inhalation of pre-mixed, ready-to-use liquid forms of Colistimethate. The side effects are as a result of local toxicity to the lung and airway. More details of these effects are provided in the Information for Healthcare Professional.
Healthcare professionals who treat patients with CF should work out a treatment plan with their patients that best meets their needs.
Patients and/or their caregivers with questions or concerns about this advisory should contact their healthcare provider or their Cystic Fibrosis Care Center to determine how best to continue treating their infection. [Patients who have been diagnosed with lung problems after inhaling Colistimethate should also contact the law firm of Pritzker | Ruonhonen for a free consultation regarding a possible Colistimethate lawsuit. Families of patients who have died after inhaling Colistimethat should contact Pritzker | Olsen, P.A. regarding a wrongful death lawsuit.]

You can find more details about Colistimethate in FDA’s Information for Healthcare Professionals and in the full prescribing information for Colistimethate.

The FDA urges both healthcare providers and patients to report side effects from medical products to MedWatch. MedWatch reports may be made by phone: 1-800-FDA-1088; fax: 1-800-FDA-0178; or via the Internet at http://www.fda.gov/medwatch/index.htm.

For liquid Colistimethate lawsuit information, including possible malpractice lawsuits against a pharmacy and prescribing doctor, please contact Pritzker | Olsen, P.A. for a free consultation. Call toll-free at 1-888-377-8900 or submit the Pritzker | Olsen, P.A. online consultation form.

Free Case Consultation

Firm News

Fred Pritzker Listed in The Best Lawyers in America

Fred Pritzker has been notified that he will again be listed in The Best Lawyers in America for his work in personal injury litigation.

Attorney Elliot Olsen Speaks at Conference

Attorney Elliot Olsen recently spoke at the Seventh Annual LifeScience Alley Conference in Minneapolis on Preemption and the Future of Medical Device Litigation. He appeared with Randall Pattee of Lindquist and Vennum and Jean Lance, VP of corporate legal and general counsel for Boston Scientific.

Zicam Lawsuit

Several lawsuits have been filed alleging Zicam caused loss of smell (anosmia) and taste, and our lawyers are reviewing potential claims. We are gathering information about Zicam smell loss. Read more about Zicam: Zicam class action lawsuit, warning letter from the FDA to Matrixx Initiatives, Inc. regarding Zicam Cold Remedy nasal spray and gel swabs, Zicam recall.

After only one use of a Zicam Cold Remedy product, Bonnie Blodgett lost her sense of smell. A gradening writer and foodie, her life was drastically changed. She recently published Remembering Smell: A Memoir of Losing--and Discovering--the Primal Sense in which she chronicals her experience with losing her sense of smell and then slowly getting it back again.

Bonnie's experience with Zicam is similar to many of our other clients. They experienced a burning sensation during the first use of a Zicam product and then lost their sense of smell (anosmia). Most of them were not as fortunate as Bonnie and have not regained their sense of smell.

For more information about Remembering Smell, please click on the image of the book.

Ortho Evra Lawsuit: Ortho Evra Birth Control Patch

The Ortho Evra birth control patch has been linked to an increased risk of blood clots that can lead to pulmonary embolism, stroke and heart attack.

Fentanyl Lawsuit and Fentanyl Recall

There have been a number of recalls regarding fentanyl due to the risk of a fentanyl overdose.

This is attorney advertising. Past results do not guarantee a similar outcome. The result of each case is determined by the specific facts and the applicable law.